<DOC>
	<DOCNO>NCT02374450</DOCNO>
	<brief_summary>The purpose pre-licensure cohort study estimate incidence adverse event special interest ( AESI ) , adverse event ( AE ) lead hospitalisation death , meningitis malaria sub-Saharan African child 5 year age . The outcome study provide baseline data post-licensure EPI-MALARIA-003 ( 115056 ) study evaluate safety , effectiveness impact RTS , S/AS01E vaccine . An interim analysis perform RTS , S/AS01E vaccine implement study site . This interim analysis do clean data collect sub-group subject 6 month follow-up follow administration dose 3 DTP/HepB/Hib vaccine ( 6 12 week group ) , 6 month Visit 3 ( 5-17 month group ) ; correspond Visit 5 . The interim analysis concern primary safety endpoint main impact endpoint ( 6 month post last dose purpose interim ) .</brief_summary>
	<brief_title>A Surveillance Study Diseases Specified Adverse Events Special Interest , Other Adverse Events Leading Hospitalisation Death , Meningitis Children Africa Prior Implementation RTS , S/AS01E Candidate Vaccine</brief_title>
	<detailed_description>The outcomes interest ( AESI , AE lead hospitalization death , meningitis ) well data malaria morbidity mortality capture active enhanced hospitalization surveillance child &lt; 5 year age . Children enrol active surveillance visit home regular interval period 8 month . In addition home visit , visit health care facility record period . Thereafter continuous monitoring hospitalization ; study end day child reach 5 year age , whichever occur first . For child enrol enhanced hospitalization surveillance , hospitalization event capture total study period . The protocol summary update protocol amendment 4 ( date 11-Dec-2015 ) information : Rationale amendment 3 : - Participant recruitment modify : approximately 20,000 child enrol active surveillance 6-12 week group ( identify first administration DTP/HepB/Hib vaccine ) , mimic administration RTS , S/AS01E 6-12 week age group , 20,000 child 5-17 month group ( either select child identify first administration DTP/HepB/Hib vaccine , child age 5 &lt; 18 month correspond catch-up ) , mimic administration RTS , S/AS01E 5-17 month age group . - The term `` passive surveillance '' replace term `` enhanced hospitalization surveillance '' . - The case definition , ascertainment laboratory investigation ( include determine aetiology ) meningitis case clarify . The objective outcomes related meningitis modify accordingly . - Case ascertainment AESI clarify . - It clarify blood sampling perform per study procedure case AESI meningitis . In case neurological AESI meningitis , cerebrospinal fluid ( CSF ) sample take part routine practice , part sample store . Only serious adverse event relate blood sample collect . - Limitations due sample size study design discuss . - For clarity , consistency comparability objective , outcome methodology , protocol amendment 3 text align EPI-MALARIA-002 ( 115055 ) EPI-MALARIA-003 ( 115056 ) protocol . Rationale amendment 4 : - The background section update data cerebral malaria post-hoc analysis Phase III study MALARIA-055 . - Additional secondary objective add estimation probable meningitis estimation incidence cerebral malaria use RDT and/or microscopy . - The design analysis modify take account implementation 4th dose RTS , S/AS01E . In addition , follow-up period last dose extend correspond follow-up period child enrol EPI-MAL-003 ( i.e . 24 month 4th dose RTS , S/AS01E ) . Indeed , home visit 12 month 24 month last RTS , S/AS01E dose help capture protocol-defined disease may long risk window period may identify subject visit health care facility , monitor occurrence malaria episodes evaluation vaccine effect . The age study population adapt accordingly ( &lt; 5 year ) . - The section sit participate study update follow SAGE/MPAC recommendation pilot implementation RTS , S/AS01E 3-5 distinct setting SSA restrict moderate-to-high transmission malaria . - The activity relate home visit detect malaria case , include train community health worker systematic measurement body temperature child , availability malaria test clarify alignment EPI-MAL-003 protocol . - It clarify case malaria detect annual visit plan EPI-MAL-005 include analysis EPI-MAL-002 . However , case malaria detect EPI-MAL-005 home visit coincide home visit schedule EPI-MAL-002 , event capture EPI-MAL-002 . - The case definition malaria revise , accord 3rd edition WHO guideline treatment malaria ( 2015 ) . In addition , case definition cerebral malaria add . - Case ascertainment external panel expert clarify . - It clarify severe/cerebral malaria case AE lead hospitalization death review external panel expert . - The incidence AE lead hospitalization death , meningitis malaria morbidity mortality monitor sub-populations child hemoglobinopathy HIV-positive child . - The section analysis co-primary objective revise mention additional risk period consider base result sensitivity analysis . - The section analysis secondary objective revise clarification potential variable may consider model , line information collect eCRF , estimation incidence cerebral malaria . - It clarify interim analysis per-formed data collect subject 6 month follow-up follow administration dose 3 DTP/HepB/Hib vaccine ( 6-12 week group ) , 6 month V3 ( 5-17 month group ) . - The section handle miss data revise . - It clarify data seasonal malaria chemoprevention collect . Other change make simplification , clarification consistency .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Meningitis</mesh_term>
	<criteria>All subject must satisfy ALL follow criterion study entry : Subjects ' parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] , opinion investigator , comply requirement protocol . Written inform consent provide either parent ( ) LAR subject . Subject live Health Demographic Surveillance System ( HDSS ) area . For enrolment active surveillance : child must &lt; 18 month age . OR For enrolment enhance hospitalisation surveillance : child must &lt; 5 year age hospitalise time study . Child care .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Surveillance study</keyword>
	<keyword>Adverse Events Specific Interest ( AESI )</keyword>
	<keyword>Children</keyword>
	<keyword>Infants</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Epidemiology</keyword>
	<keyword>Serious Adverse Events ( SAE )</keyword>
	<keyword>Africa</keyword>
</DOC>